Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy

This publication has 24 references indexed in Scilit:

• Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer
  Annals of Oncology, 2006
• Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group
  Journal of Clinical Oncology, 2005
• Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
  Clinical Cancer Research, 2004
• High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer
  New England Journal of Medicine, 2003
• Repeated observation of breast tumor subtypes in independent gene expression data sets
  Proceedings of the National Academy of Sciences, 2003
• Cellular roles of DNA topoisomerases: a molecular perspective
  Nature Reviews Molecular Cell Biology, 2002
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
  Proceedings of the National Academy of Sciences, 2001
• ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy
  European Journal Of Cancer, 2000
• Neu-Protein Overexpression in Breast Cancer
  New England Journal of Medicine, 1988
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987